Dr William Tillett highlights missed opportunities for early intervention in psoriatic arthritis and action for clinicians to ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025 Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, ...

Original Medicare will launch a multi-state pilot program requiring prior authorization for certain devices, procedures, and ...

The tragic history behind Springsteen’s darkest album that inspired new biopic - US CULTURE: In ‘Deliver Me From Nowhere’, ...

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 ...

In a separate, post-hoc analysis of adolescent patients who had been diagnosed with severe AA less than two years before starting treatment, 80% of those receiving baricitinib 4 mg and 64.3% receiving ...